Sign inJoin waitlistJoin the waitlist

Douglas Laux

Co-Leader of the Head and Neck Cancer MOG, Clinical Associate Professor · University of Iowa Health Care Medical Center

Credentials: · · · · · · ·

History

Clinical Associate Professor · University of Iowa Health Care Medical Center
Present
University of Iowa Health Care Medical Center
Present
University of Iowa Health Care Medical Center
Present

Hematology and Medical Oncology
University of Iowa Health Care Medical Center
2008–2011
Internal Medicine
Case Western Reserve University
2005–2008
University of Missouri School of Medicine
2001–2005

Research

Methylation profiling of CpG islands in human breast cancer cells
Human Molecular Genetics · 1999 · Last of 3 authors · 321 citations
CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer
Clinical Cancer Research · 2000 · 122 citations
Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique
Cancer Research · 1997 · 100 citations

Mohammed Milhem
4 papers
Charles Caldwell
2 papers
JR
John Rieth
2 papers · 1 as a fellow
John Smestad
2 papers · 2 as a fellow
Muhammad Furqan
2 papers
Adil Daud
1 paper
Anthony Snow
1 paper
AJ
Asad Javed
1 paper
BD
Brennan Decker
1 paper
Brent Hanks
1 paper
Carryn Anderson
1 paper
Cesar Perez
1 paper

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $906.9K · University of Iowa
2000–2026

Clinical trials

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Site PI · Not yet recruiting · Phase 3
Corbus Pharmaceuticals Inc.
2026–2029
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Site PI · Recruiting · Phase 3
ECOG-ACRIN Cancer Research Group
2024–2030
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2024–2029
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Site PI · Recruiting · Phase 2
Weill Medical College of Cornell University
2023–2028